# Indaptus Therapeutics Inc. (INDP) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.24, market value $432 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Indaptus Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 38.1×**. The shares trade at 38.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -661.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 52.0%**. Earnings per share rose 52.0%.

## Financial health
- **Current ratio: 1.51** (quick 1.51). Current assets cover the next year's liabilities 1.51 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Indaptus Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 8.7%** (YTD 20.3%, 3-mo 167.2%). The shares are up 8.7% over twelve months including dividends.
- **From 52-week high: -45.6%** (252.2% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 2.15** (volatility 205%). Beta of 2.15 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INDP · Page: https://foliofundamentals.com/stocks/indp

Not investment advice.